Neurocrine Biosciences Inc. (NASDAQ: NBIX) announced results from a post-hoc analysis of its KINECT 4 clinical trial showing that 94% of participants treated with INGREZZA achieved either symptomatic remission or a clinically meaningful response in tardive dyskinesia treatment.

The 48-week study analysis found that among patients who did not meet the stringent symptomatic remission threshold, 86% achieved at least a 30% reduction in total Abnormal Involuntary Movement Scale scores, while 67% achieved at least a 50% reduction. The company presented these findings at the 2026 Psych Congress Elevate conference.

A separate Medicare claims analysis of more than 176,000 patients newly diagnosed with tardive dyskinesia revealed that 90% had at least one hepatic risk factor and 44% had three or more risk factors. These factors included metabolic conditions such as diabetes, hypertension and obesity, as well as substance use-related factors associated with liver disease.

"This new analysis demonstrates that approximately 94% of patients treated with INGREZZA for 48 weeks either achieved symptomatic remission or experienced clinically meaningful reductions in their tardive dyskinesia movements," said Sanjay Keswani, the company's chief medical officer.

The KINECT 4 study involved 163 participants with moderate to severe tardive dyskinesia who received 48 weeks of treatment with INGREZZA. Previously reported data showed that 59% of patients achieved symptomatic remission, defined as minimal or no involuntary movements across seven body regions.

INGREZZA is approved by the Food and Drug Administration for treating tardive dyskinesia in adults and chorea associated with Huntington's disease. The drug is a selective vesicular monoamine transporter 2 inhibitor that works by reducing dopamine signaling in the brain.